• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    115.03 +3.96 (+3.57%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 969,081
    Open 111.51
    Bid (Size) 112.75 (100)
    Ask (Size) 130.03 (100)
    Prev. Close 111.07
    Today's Range 109.17 - 115.87
    52wk Range 47.89 - 114.99
    Shares Outstanding 38,297,975
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +47.3%
    +47.3%
    1 Month
    +16.3%
    +16.3%
    3 Month
    +30.9%
    +30.9%
    6 Month
    +43.7%
    +43.7%
    1 Year
    +128.8%
    +128.8%

    More News

    Read More
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
    Via Chartmill
    News headline image
    Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
    Via MarketBeat
    News headline image
    Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharma: A Rare Disease Growth Story to Watch ↗
    Via MarketBeat
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
    Via The Motley Fool
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
    Via The Motley Fool
    News headline image
    Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum Pharma (MIRM) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property

    Frequently Asked Questions

    Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
    Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
    What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
    Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
    The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
    What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
    The current price of Mirum Pharmaceuticals, Inc. - common stock is 115.03
    When was Mirum Pharmaceuticals, Inc. - common stock last traded?
    The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 06/24/26 04:00 PM ET
    What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
    The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 4.41B
    How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
    Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.